Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

PURPOSE: BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-in...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: Peters, Solange, Gettinger, Scott, Johnson, Melissa L., Jänne, Pasi A., Garassino, Marina C., Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A., Chaft, Jamie E., Carcereny Costa, Enric, Patel, Jyoti D., Chow, Laura Q.M., Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A., Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2017
主題:
ORIGINAL REPORTS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562171/
https://ncbi.nlm.nih.gov/pubmed/28609226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.9476
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍